Preliminary data from the phase 1/2 study of TP-3654, an investigational selective PIM1 kinase inhibitor, showed cytokine reduction and clinical responses in relapsed/refractory myelofibrosis (MF) Meeting Abstract
| Authors: | El Chaer, F.; Rein, L.; Shimoda, K.; Yuda, J.; Haque, T.; McCloskey, J.; Takami, A.; Fukaya, M.; Shirane, S.; Kabir, S.; Mei, J.; Seki, M.; Li, Z.; Wade, M.; Lebedinsky, C.; Rampal, R. K. |
| Abstract Title: | Preliminary data from the phase 1/2 study of TP-3654, an investigational selective PIM1 kinase inhibitor, showed cytokine reduction and clinical responses in relapsed/refractory myelofibrosis (MF) |
| Meeting Title: | 11th Annual Meeting of the Society of Hematologic Oncology (SOHO 2023): Progress in Personalized Therapy |
| Keywords: | myelofibrosis; cytokine; phase i; pim1; mpn; tp-3654 |
| Journal Title: | Clinical Lymphoma, Myeloma and Leukemia |
| Volume: | 23 |
| Issue: | Suppl. 1 |
| Meeting Dates: | 2023 Sep 6-9 |
| Meeting Location: | Houston, TX |
| ISSN: | 2152-2650 |
| Publisher: | Elsevier Inc. |
| Date Published: | 2023-09-01 |
| Start Page: | S395 |
| End Page: | S396 |
| Language: | English |
| ACCESSION: | WOS:001062479600377 |
| PROVIDER: | wos |
| DOI: | 10.1016/S2152-2650(23)01244-2 |
| Notes: | Meeting Abstract: MPN-439 -- Source: Wos |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work